|
|
Volumn 4, Issue 5, 2002, Pages 435-436
|
|
Immunotherapy for CMV infection
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CD4 ANTIGEN;
CD8 ANTIGEN;
GANCICLOVIR;
VIRUS PROTEIN;
TUMOR ANTIGEN;
ADOPTIVE IMMUNOTHERAPY;
ALLOTRANSPLANTATION;
ANTIVIRAL ACTIVITY;
CELL CLONING;
CELL CULTURE;
CELL ISOLATION;
CLINICAL TRIAL;
CONFERENCE PAPER;
CYTOMEGALOVIRUS INFECTION;
CYTOTOXIC T LYMPHOCYTE;
CYTOTOXICITY;
DONOR;
DRUG EFFECT;
DRUG SAFETY;
EPSTEIN BARR VIRUS;
FATALITY;
GRAFT VERSUS HOST REACTION;
HLA MATCHING;
HUMAN;
IMMUNOTHERAPY;
INCIDENCE;
INFECTION CONTROL;
INFECTION RISK;
LYMPHOPROLIFERATIVE DISEASE;
MONOCYTE;
MORTALITY;
NONHUMAN;
PROPHYLAXIS;
STEM CELL TRANSPLANTATION;
T LYMPHOCYTE;
VIRUS INFECTION;
VIRUS LOAD;
VIRUS TRANSMISSION;
CD8+ T LYMPHOCYTE;
CYTOMEGALIC INCLUSION BODY DISEASE;
IMMUNOLOGY;
LYMPHOCYTE;
METABOLISM;
METHODOLOGY;
REVIEW;
TIME;
ANTIGENS, NEOPLASM;
CD8-POSITIVE T-LYMPHOCYTES;
CYTOMEGALOVIRUS INFECTIONS;
GRAFT VS HOST DISEASE;
HUMANS;
IMMUNOTHERAPY;
LYMPHOCYTES;
T-LYMPHOCYTES;
TIME FACTORS;
|
|
EID: 0036436462
PISSN: 14653249
EISSN: None
Source Type: Journal
DOI: 10.1080/146532402320776080 Document Type: Conference Paper |
|
Times cited : (10)
|
|
References (1)
|
